sp should be 5x imho, page-727

First 727 Last

Share
Profile

Follow
Shellbell

7,945 Posts.

3407

08/07/21

09:21

Post #: 54360199
Share

Originally posted by BigDaniel: ↑

Great points and find Shell.

It is very interesting to speculate what the early or NOW monetization of OmniCar might look like.

Whether that's an early licensing agreement? Or a collaboration of IP or combination of both even? Perhaps like you said it involves the assisted funding of trials?

I have certainly entertained the idea of joint ventures/partial sales as I mentioned last week, however I'm strongly leading towards the joint venture aspect and licensing rather than an early sale.

I wonder if those billion dollar companies on the web are in direct interest of PTX itself or the broader technology? You may be onto something right there? Exciting, if not with those mentioned companies I'm 99% sure now we are going to see a red hot announcement regarding a partner and OmniCar sooner than later.

We would have to be at the top of the list for interested parties, knowing we are only one of 3 companies developing multi ligand treatments that can attack multiped targets or evolving targets.

I think it's all well & good for some Car-T parties to be dismissive of OmniCar or similar programs but as these programs progress, if successful will be hard to dismiss.

The safety, effectiveness, cost and versatility of current Car-T therapy is such that should a competitor have access to something like OmniCar targeting the same cancer, it could quickly put them out of business.

What Oncologist is going to pick a conventional Car-T therapy over an OmniCar/Car-T treatment that is...

1- Far safer with low toxicity & a treatment that can be turned on and off at the Oncologists command.

2- Can continue to target solid tumors rather than losing potency & being limited to treating blood cancers as the antigens fade.

3- Is versatile and can have multiple ligands added at any point to the antigens to target multiple or mutated cancers, as PTX explained in the presentation that mutation is often very rapid with many cancers and there is simply no time to adapt the treatment where OmniCar can plug and play instantly which will ultimately mean life or death for many.

Programs like OmniCar may become mandated by health authorities in the future for all we know? Kind of like safety packages for cars are now.

Cheers.

Expand

Thanks for the great reply post! Further to our discussion on the potential for collaborations in the US, Loxo Oncology which PTX reference on their website has "collaboration" written all over it.. to the extent that they devote a page to "Partners"....

https://www.loxooncology.com/

PTX Price at posting: 24.5¢ Sentiment: Buy Disclosure: Held
19 Upvote

2 Great analysis

Reply

Top Stories

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 311 more messages in this thread...

First 727 Last

Add PTX (ASX) to my watchlist

(20min delay)
Last 4.7¢		Change 0.002(4.44%)		Mkt cap ! $37.85M

Open	High	Low	Value	Volume
4.6¢	4.9¢	4.6¢	$32.17K	677.4K

Buyers (Bids)

No.	Vol.	Price($)
1	25682	4.7¢

Sellers (Offers)

Price($)	Vol.	No.
4.8¢	221710	2

View Market Depth

No.	Vol.	Price($)
1	25682	0.047
1	170999	0.046
2	25000	0.045
2	65454	0.044
1	70000	0.043

Price($)	Vol.	No.
0.048	221710	2
0.049	228740	4
0.050	236935	5
0.051	19607	1
0.052	60000	1

Last trade - 14.32pm 07/10/2024 (20 minute delay)

PTX (ASX) Chart

sp should be 5x imho, page-727

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

sp should be 5x imho, page-727

Top Stories

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News